• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

DNA from tampons may be a sensitive test for high-grade ovarian cancer

byMaren ShapiroandLeah Hawkins Bressler, MD, MPH
October 13, 2014
in Obstetrics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In a small study of five women, vaginal DNA from tampons had a 60% sensitivity for detecting high-grade serous ovarian cancer in women with intact fallopian tubes.

Evidence Rating Level: 3 (Average)

Study Rundown: Ovarian cancer is the most deadly of all female cancers, killing an estimated 14 000 women in the United States last year alone. Symptoms of ovarian cancer are typically nonspecific, such as bloating or abdominal pain, and complicate early diagnosis. Unlike pap smears for cervical cancer, there is no effective screening test for ovarian cancer, so most women are diagnosed at a more advanced stage. Because the ovaries are connected to the uterus, cervix and vagina through the fallopian tubes, researchers hypothesized that cancer cells might exfoliate off ovarian tumors and be detected in cell samples from the vagina. To test this theory, they used tampons to collect vaginal cell samples from women undergoing surgery for ovarian masses and looked for TP53 gene mutations (found in most epithelial ovarian cancers) in the tampon samples of women with intact fallopian tubes, diagnosed with high-grade ovarian cancer.

In a small sample size of only five women, TP53 gene mutations were present in 3 tampon samples, giving the test a sensitivity of 60% for detecting high-grade ovarian cancer. Strengths of this study include its unique concept—if successful, this technology might offer non-invasive, early detection of ovarian cancer. Limitations include very small sample size and inclusion of only women with high-grade ovarian tumors. Further investigation to determine clinically utility in the general population, where the prevalence of ovarian cancer is very low, is merited.

Click to read the study in Obstetrics & Gynecology

Click to read an accompanying editorial in Obstetrics & Gynecology

Relevant Reading: Drive mutations in TP53 are ubiquitous in high-grade serous carcinoma of the ovary

RELATED REPORTS

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

In-Depth [pilot study]: Researchers enrolled 33 women undergoing surgery for a pelvic mass at a gynecologic oncology clinic. A vaginal tampon was placed prior to surgery and removed in the operating room. In women who were diagnosed with advanced serous carcinoma, DNA was extracted from both cells trapped in the tampon and the tumor and tested for a TP53 mutation. For DNA detection, researchers used a highly sensitive, novel method able to detect rare gene mutations in a mixed DNA sample.

Of the women originally enrolled, 8 were diagnosed with high-grade cancer; five had intact fallopian tubes and were included in the final analysis. TP53 mutations were detected in all tumor samples, and in the tampon samples from 3 of 5 participants, for a sensitivity of 60%. In all 3 cases of successful detection, the mutation identified from vaginal DNA was identical to that in the ovarian tumor.

More from this author: Contained morcellation for benign gynecologic surgeries feasible, minimize surgical risk, Oocyte vitrification not associated with adverse obstetric or perinatal outcomes, IUD contraception equally safe in teenagers as in older women, No-cost contraception reduces unintended pregnancy rates, 20% lifetime risk of pelvic floor surgery in women

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: ovarian cancerTP53 gene
Previous Post

Risk of HBV reactivation associated with rituximab-containing chemotherapy

Next Post

Robotic adnexal surgeries may have more complications than laparoscopic

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

June 30, 2022
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Oncology

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

March 21, 2022
The SOLO1 trial: Olaparib significantly delays progression of advanced ovarian cancer
Chronic Disease

Trametinib improves progression-free survival among patients with low-grade serous ovarian carcinoma

February 15, 2022
Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial
Chronic Disease

Adavosertib compared with active monitoring is potentially effective against TP53/RAS-mutant metastatic colorectal cancer.

October 3, 2021
Next Post
Single-site robotic cholecystectomy is safe, but technically challenging

Robotic adnexal surgeries may have more complications than laparoscopic

Internal monitors associated with fever in laboring mothers

Increased nuchal translucency linked to progesterone therapy

Classics Series, Landmark Trials in Medicine

Albumin in cirrhotic patients with spontaneous bacterial peritonitis [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
  • The RAPTURE trial: Radiofrequency ablation effective and safe in lung cancer [Classics Series]
  • Relugolix combination therapy is efficacious for endometriosis-associated pain
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.